Adults taking semaglutide for obesity lost about 15% of their body weight over 60 weeks and, in the same trial, showed fewer binge eating episodes and less body dissatisfaction than those on placebo. The randomized controlled trial, led at the University of Pennsylvania and published in the International Journal of Eating Disorders, is among the first to test whether the widely prescribed GLP-1 medication worsens — or eases — disordered eating.
That question matters because it has been an open worry. As GLP-1 receptor agonists like semaglutide 2.4 mg (sold as Wegovy for weight management) have run through obesity clinics worldwide, clinicians have asked whether appetite suppression could feed restrictive or compensatory eating patterns in vulnerable patients.
The new data suggest the opposite trend, on average — but with an important caveat buried in the fine print: a small number of participants did develop disordered eating behaviors during the study.
“These results are encouraging, particularly for patients who struggle with both obesity and binge eating,” said Kelly Costello Allison, PhD, director of Penn’s Center for Weight and Eating Disorders and the study’s first author, who presented the findings at ObesityWeek 2026 in Washington, D.C. “At the same time, our findings highlight the importance of routinely assessing eating behaviors throughout treatment, particularly in patients with an eating disorder history, so that patients who develop concerning symptoms can receive appropriate care.”
In Plain English: The Clinical Takeaway
- In a 60-week randomized trial, people on semaglutide reported less loss-of-control eating, less body dissatisfaction, and less overall eating-disorder pathology than people on placebo — not more.
- Those who began the study with binge eating episodes were more likely to stop bingeing entirely while on the medication.
- This does not mean the drugs are risk-free for everyone; a few participants did show concerning eating patterns, so anyone with an eating disorder history should be monitored during treatment.
How the 60-Week Trial Was Built
The study enrolled 120 adults seeking obesity treatment, all with a body mass index above 27 kg/m². Researchers randomized them — in a 3:2 ratio, according to the published abstract — to receive weekly semaglutide 2.4 mg or a placebo injection, with both groups also receiving a structured lifestyle intervention covering dietary counseling and physical activity guidance.
Clinicians did not rely on self-report alone. At baseline and at weeks 20, 40, and 60, they conducted the Eating Disorder Examination, a structured clinical interview considered the reference standard for assessing binge eating and eating-disorder psychopathology. Questionnaires measured loss of control over eating, drive for thinness, body dissatisfaction, and mood (via the PHQ-9 depression screen).
What the Numbers Showed
The headline weight figures are familiar from prior semaglutide trials: roughly 15% average body-weight loss in the treatment arm versus about 3% on placebo at 60 weeks. What’s new is the psychological layer on top. The semaglutide group showed significantly greater reductions in loss-of-control eating, global eating-disorder pathology, weight and shape concern, drive for thinness, and body dissatisfaction at several timepoints, per the study abstract.
| Measure | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Average weight loss at 60 weeks | ~15% of body weight | ~3% of body weight |
| Participants enrolled | 120 adults (randomized 3:2) | |
| Those with baseline binge episodes | n = 31; more likely to achieve abstinence on semaglutide | |
| Full or subthreshold binge-eating disorder | n = 18; more likely to achieve remission on semaglutide | |
| New eating disorder symptoms | Rare in both groups | |
One nuance deserves attention: binge frequency reductions did not differ significantly between groups overall. The remission signal came specifically from the subgroups who entered the trial with binge episodes (n = 31) or full or subthreshold binge-eating disorder (n = 18), who were more likely to achieve abstinence on semaglutide.
That distinction — symptom scores improving broadly, but abstinence improving in the bingers — is the kind of detail that shapes how psychiatrists will read this study.
A Plausible Mechanism, but Not a Proven One
The mechanism of action here is biologically coherent even though the trial was not designed to prove it. Semaglutide mimics glucagon-like peptide-1, a gut hormone that slows gastric emptying and acts on hypothalamic appetite centers to increase satiety.
Prior neuroimaging work on GLP-1 drugs has suggested reduced activation in brain reward regions in response to food cues, though the Penn trial did not measure this directly, and I won’t overstate what it can’t show.
Study Funded by Novo Nordisk Investigator Grant
Transparency note: the study was funded in part through a research grant from the Novo Nordisk NNI Investigator Sponsored Studies Program, according to Newswise’s release of the Penn announcement. The sponsor, per that release, “played no role in the study’s design, conduct, analysis, interpretation, or reporting.”
Investigator-initiated funding still comes from the drug’s manufacturer, so readers should weigh that context — while also noting that the placebo-controlled design and clinician-graded assessments are the strongest safeguards against bias available in a trial of this size.
Semaglutide Approved for Weight Management
Semaglutide 2.4 mg is already approved for chronic weight management by the U.S. Food and Drug Administration and by the European Medicines Agency, and it is prescribed within NHS specialist weight-management services in the UK. This study does not change those approvals — it addresses a safety question regulators and clinicians have been asking informally for years.
Authors Urge Monitoring for Disordered Eating Symptoms
On the eating-behavior front, the trial’s own authors urge vigilance. Anyone on a GLP-1 medication who notices new or worsening disordered eating symptoms or body image concerns should raise them with their prescribing clinician promptly, as the researchers stress the importance of continued monitoring during treatment.
The Open Question
With 120 participants, this trial can describe averages but cannot promise outcomes for individuals — and the authors themselves note that larger studies are needed, particularly in people with diagnosed binge-eating disorder or other eating disorder histories.
“Our findings suggest that semaglutide not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss of control eating in many patients,” said Jena Tronieri, PhD, senior research investigator at Penn’s CWED and senior author of the study. Whether those improvements hold — and for whom they don’t — is the question the next, larger trials must answer.
References
- Allison KC, Wadden TA, DeRouen K, et al. “Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m² Treated by Semaglutide: A 60-Week Randomized Placebo-Controlled Trial.” International Journal of Eating Disorders, 2026. DOI: 10.1002/eat.70253. International Journal of Eating Disorders
- University of Pennsylvania Perelman School of Medicine press release, distributed via Newswise, November 2026.
- News-Medical, “Semaglutide reduces binge eating symptoms and body dissatisfaction,” November 2026.
- Medical Xpress, “Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment,” November 2026.
Consult a qualified healthcare professional before starting, stopping, or changing any medication.